Andrew Dmytrijuk, MD | Authors

Eltrombopag for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura

December 01, 2009

On November 20, 2008, the US Food and Drug Administration (FDA) granted accelerated approval for eltrombopag (Promacta Tablets, GlaxoSmithKline) for the treatment of thrombocytopenia in patients with chronic immune thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulin therapy, or splenectomy.